

Important Update: Monoclonal Antibody Treatment

There is new information regarding how you bill for the products and administration of monoclonal antibody treatment for your patients. Please see **Billing Information** below for the latest information.

Updates

Effective August 15, 2022, the US Government is directing health care providers to purchase Bebtelovimab directly from the manufacturer Eli Lilly. Reimbursement for this product is eligible for dates of service on or after August 15, 2022. Products supplied by the government will not be eligible for reimbursement. Providers should only bill for commercially purchased products.

CPT Codes for Monoclonal Antibody Therapy

The table below provides a list of the most recent treatments covered by Florida Blue. Please review the effective dates as some of these treatments no longer have emergency use authorization and are not covered.

HCPCS Code	HCPCS Short Descriptor	Labeler Name	National Payment Allowance Effective for Claims with DOS on or after 05/6/2021	Effective Dates
Q0222	Bebtelovimab 175 mg	Eli Lilly	\$2,394.00 ^[1]	02/11/2022 – TBD
Q0249	Tocilizumab for COVID-19	Genentech	\$6.57	06/24/2021 – TBD
M0222	Bebtelovimab injection	Eli Lilly	\$350.50 ^[2]	02/11/2022 – TBD
M0223	Bebtelovimab injection home	Eli Lilly	\$550.50 ^[2]	02/11/2022 – TBD
M0249	Adm Tocilizu COVID-19 1st	Genentech	\$450.00 ^[2]	06/24/2021 – TBD
M0250	Adm Tocilizu COVID-19 2nd	Genentech	\$450.00 ^[2]	06/24/2021 – TBD
The medications below are no longer covered as they no longer have emergency use authorization.				
M0239	Bamlanivimab-xxxx infusion	Eli Lilly	Code not active during this time period	11/10/2020 – 04/16/2021
M0240	Casiri and imdev repeat	Regeneron	\$450.00 ^[2]	07/30/2021 – 01/24/2022
M0241	Casiri and imdev repeat hm	Regeneron	\$750.00 ^[2]	07/30/2021 – 01/24/2022
M0243	Casirivi and imdevi inj	Regeneron	\$450.00 ^[2]	11/21/2020 – 01/24/2022

M0244	Casirivi and imdevi inj hm	Regeneron	\$750.00 ^[2]	05/06/2021 – 01/24/2022
M0245	Bamlan and etesev infusion	Eli Lilly	\$450.00 ^[2]	02/09/2021 – 01/24/2022
M0246	Bamlan and etesev infus home	Eli Lilly	\$750.00 ^[2]	05/06/2021 – 01/24/2022
M0247	Sotrovimab infusion	GSK	\$450.00 ^[2]	05/26/2021 – 04/05/2022
M0248	Sotrovimab inf, home admin	GSK	\$750.00 ^[2]	05/26/2021 – 04/05/2022
Q0239	Bamlanivimab-xxxx	Eli Lilly	Code not active during this time period	11/10/2020 – 04/16/2021
Q0240	Casirivi and imdevi 600mg	Regeneron	\$0.010 ^[1]	07/30/2021 – 01/24/2022
Q0243	Casirivimab and imdevimab	Regeneron	\$0.010 ^[1]	11/21/2020 – 01/24/2022
Q0244	Casirivi and imdevi 1200 mg	Regeneron	\$0.010 ^[1]	06/03/2021 – 01/24/2022
Q0245	Bamlanivimab and etesevima	Eli Lilly	\$0.010 ^[1]	02/09/2021 – 01/24/2022
Q0247	Sotrovimab	GSK	\$2,394.00	05/26/2021 – 04/05/2022

Visit [CMS's website](#) for more information on payment allowances and effective dates for COVID-19 Vaccines and Monoclonal Antibodies during the Public Health Emergency.

Billing Information

For Commercial plan patients, if your facility provides monoclonal antibody treatment for COVID-19, please bill Florida Blue using the appropriate CPT code for covered infusion therapy for the **administration and the drug, if purchased commercially through the manufacturer**. Drugs supplied to providers by the government should not be submitted to Florida Blue for billing. Your Florida Blue patients will be responsible for their normal cost share. You can check patient eligibility and benefits through Availity^{®3} on [availity.com](#).

Updated: For Medicare Advantage plan patients you treat or treated on or after January 1, 2022 (except for most Medicare Advantage hospice patients), submit claims for **administering** COVID-19 monoclonal antibody products to Florida Blue Medicare. Original Medicare stopped paying these claims starting January 1, 2022. For services performed on or before December 31, 2021, providers should bill Original Medicare for the administration reimbursement.

¹Providers should not bill for the product if they received it for free.

²These rates will be geographically adjusted for many providers. For providers and suppliers with payments that are geographically adjusted by the methodology used by the Medicare Physician Fee Schedule (MPFS), files with the geographically adjusted payment rates for monoclonal antibody administration are included in the "Additional Resources" section below. Certain settings utilize other payment methodologies, such as payment based on reasonable costs.

³Availity, LLC is a multi-payer joint venture company. For more information or to register, visit [availity.com](#). Florida Blue is an Independent Licensee of the Blue Cross and Blue Shield Association.

Florida Blue is an Independent Licensee of the Blue Cross and Blue Shield Association.